OptimizeRx Corporation Reports Third Quarter 2016 Results

ROCHESTER, Mich., Nov. 07, 2016 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to offer doctors valuable product information and patient support right at point of prescribe, reported results for the third quarter ended September 30, 2016.

Q3 2016 Highlights & Subsequent Events

  • In October, the company announced independent research results confirming OptimizeRx delivered pharmaceutical brands a return on investment that ranged from 300% to 1,200%.
  • In October, the company expanded its partnership with Allscripts, a global leader in healthcare information technology solutions, to increase focus on clinical messaging for pharmaceutical companies.
  • Financial messaging, i.e., eCoupons, distributed for 75 brands in the third quarter of 2016, up from 71 brands in the third quarter of 2015 and continued testing of the market with 60 generic financial assistance programs.
  • Gross margin was $1.1 million or 59% of net revenue in the third quarter of 2016, as compared to $1.0 million or 48% of net revenue in the third quarter of 2015. The increase was due to a favorable product mix shift to higher margin brand support.
  • Cash and cash equivalents totaled $7.6 million at September 30, 2016, as compared to $7.6 million at June 30, 2016.
  • Completed re-branding of the company in the quarter to demonstrate its ability to provide financial and clinical messaging as well as brand support services, such as drug file integration and sales force training.

Q3 2016 Financial Summary
Net revenue in the third quarter of 2016 was $1.8 million versus $2.0 million in the same year-ago quarter. The decrease in net revenue was due to a number of brand programs completing ROI studies requested by large pharmaceutical clients. The company expects that the studies will confirm that the OptimizeRx platform substantially increases total prescriptions for its promoted brands given the platform’s very positive history with these ROI evaluations. In fact, the company recently announced publicly the results of independent research studies demonstrating that OptimizeRx delivered pharmaceutical brands a return on investment ranging from 300% to 1,200%.

Operating expenses in the third quarter of 2016 were $1.3 million, as compared to $0.9 million in the same year-ago quarter. The increase was primarily due to an increase in expenses related to growth initiatives, including investments in the company’s executive and sales team and related marketing and travel. Since the third quarter of 2015, the company has appointed a vice president of client services, a senior vice president of business development, a senior vice president of product and strategy, an additional vice president of sales, a director of sales, a vice president of channel development, and a new CEO.

Net loss was $243,000 or $(0.01) per basic share, as compared to net income of $88,000 or $0.00 per share in the same year-ago quarter.

Cash and cash equivalents totaled $7.6 million at September 30, 2016, as compared to $7.6 million at June 30, 2016. The company continued to operate debt-free.

First Nine Months of 2016 Financial Summary
Net revenue in the first nine months of 2016 increased 5% to a record $5.5 million from $5.2 million in the same year-ago period.

Operating expenses increased to $4.1 million as compared to $2.7 million in the same year-ago period. The increase was primarily due to increased human resource costs and professional fees related to growth initiatives as described above.

Net loss totaled $1.2 million or $(0.04) per share, as compared to a loss of $180,000 or $(0.01) per basic share in the same year-ago period.

Management Commentary
“In Q3, we rebranded our company from one product to multiple services in and around point-of-care,” said OptimizeRx CEO William Febbo. “We rolled out new marketing materials to better represent our ability to provide not only financial messaging, but clinical messaging and brand support services. These tools will allow for more up-sell opportunities to existing clients. In addition, we continue to invest in our sales team as demonstrated by placing an account manager within one of the WPP companies to manage that relationship.”

“We recently expanded our partnership with Allscripts to increase and diversify our revenue base. In particular, we acquired all of their LogRx (messaging within EHR) inventory for the remainder of 2016 and 2017, which has the effect of making us their exclusive partner allowing us to sell the messaging solution and extend our point of care solutions that we bring to the medical community.”

“Looking ahead, we expect a resumption in top-line growth both sequentially and year-over-year in the current quarter, primarily driven by recommencing brands currently in ROI studies, signing new brands, as well as continued expansion of financial messaging, clinical messaging and brand support.”

Conference Call
OptimizeRx will host a conference call today to discuss the third quarter 2016, followed by a question and answer period.

Date: Monday, November 7, 2016
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-877-627-6544
International dial-in number: 1-719-325-4874
Conference ID: 6212792

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 28, 2016, as well as available for replay via the Investors section of the OptimizeRx website at www.optimizerxcorp.com.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 6212792

The company expects to file its quarterly report on Form 10-Q today.

About OptimizeRx Corp
Based in Rochester, MI, OptimizeRx Corporation (OTCQB:OPRX) is a health technology software company that is revolutionizing the point of care experience through technology to improve clinical decisions and outcomes. OptimizeRx’s unique consumer and physician platforms help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.

The company’s core product replaces drug samples with electronic trial vouchers and copay coupon savings that are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading electronic health record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and other EHRs to reach over 300,000 healthcare providers. In turn, OptimizeRx promotes patient savings and support from the world’s largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go to www.optimizerxcorp.com.

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

September 30, 2016 December 31, 2015
Current Assets
Cash and cash equivalents $7,574,638 $8,207,565
Accounts receivable 2,324,343 2,847,450
Prepaid expenses 102,759 70,623
Total Current Assets 10,001,740 11,125,638
Property and equipment, net 89,273 10,239
Other Assets
Patent rights, net 789,332 832,884
Web development costs, net 376,011 340,470
Security deposit 5,049 5,049
Total Other Assets 1,170,392 1,178,403
TOTAL ASSETS $11,261,405 $12,314,280
Current Liabilities
Accounts payable - trade $191,397 $212,191
Accounts payable - related party - 570,000
Accrued expenses 42,402 6,983
Revenue share payable 2,220,703 2,355,608
Deferred revenue 766,107 227,002
Total Liabilities 3,220,609 3,371,784
Stockholders' Equity
Common stock, $.001 par value, 500,000,000 shares authorized, 29,672,132 and 29,030,925 shares issued and outstanding, respectively 29,672 29,031
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued and outstanding - -
Stock warrants 2,294,416 2,329,508
Additional paid-in-capital 33,623,051 32,185,499
Stock payable - 1,132,148
Deferred stock compensation - (13,800)
Accumulated deficit (27,906,343) (26,719,890)
Total Stockholders' Equity 8,040,796 8,942,496

For the Three Months Ended For the Nine Months Ended
September 30 September 30
2016 2015 2016 2015
NET REVENUE$ 1,786,137 $2,007,409 $ 5,458,944 $ 5,200,419
REVENUE SHARE EXPENSE 723,396 1,044,415 2,539,021 2,683,183
GROSS MARGIN 1,062,741 962,994 2,919,924 2,517,236
OPERATING EXPENSES 1,311,959 875,425 4,133,505 2,698,694
INCOME (LOSS) FROM OPERATIONS (249,218) 87,569 (1,213,582) (181,458)
Interest income 6,634 368 27,292 968
Interest expense - - (163) -
TOTAL OTHER INCOME (EXPENSE) 6,634 368 27,129 968
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES (242,584) 87,937 (1,186,453) (180,490)
NET INCOME (LOSS)$ (242,584) $87,937 $ (1,186,453) $ (180,490)
BASIC 29,433,846 23,259,837 29,374,319 23,060,787
DILUTED N/A 24,348,551 N/A N/A
BASIC$ (0.01) $0.00 $ (0.04) $ (0.01)

Company Contact:
Doug Baker
248-651-6568 x807

Investor Relations Contact:
Liolios Group
Ron Both, Senior Managing Director

Source:OptimizeRx Corporation